Acepodia, Inc. (TPEX:6976)

Market Cap	8.66B
Revenue (ttm)	301.00K
Net Income (ttm)	-655.56M
Shares Out	581.48M
EPS (ttm)	-1.14
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	536,452
Average Volume	440,950
Open	15.15
Previous Close	15.25
Day's Range	14.75 - 15.25
52-Week Range	13.80 - 25.00
Beta	0.85
RSI	43.13
Earnings Date	Nov 13, 2025

About Acepodia

Acepodia, Inc. operates as a clinical stage biotechnology company. The company engages in developing cell therapies with its antibody cell conjugation (ACC) platform technology to address cancer care. It develops AD2C targeting GPC3 for HCC which is in preclinical stage; ACE 1831 targeting CD20 that is in phase 1 clinical trial; ACE 2016 targeting EGFR, which is in Phase 1 clinical trial; ACE183 that is in phase 1 clinical trial. Acepodia Inc. has strategic clinical collaboration with Pfizer Inc. for the development of antibody-cell conjugation...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Shih-Chia Hsiao
• Country: Cayman Islands
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6976

Financial Performance

In 2024, Acepodia's revenue was 427,000, a decrease of -97.43% compared to the previous year's 16.59 million. Losses were -496.75 million, -39.22% less than in 2023.